175 related articles for article (PubMed ID: 8277209)
1. Radionuclide therapy of tumors: general aspects and considerations.
Hoefnagel CA
Int J Biol Markers; 1993; 8(3):172-9. PubMed ID: 8277209
[TBL] [Abstract][Full Text] [Related]
2. Radionuclide cancer therapy.
Hoefnagel CA
Ann Nucl Med; 1998 Apr; 12(2):61-70. PubMed ID: 9637275
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer radiopharmaceuticals.
Hoefnagel CA
Anticancer Drugs; 1991 Apr; 2(2):107-32. PubMed ID: 1958857
[TBL] [Abstract][Full Text] [Related]
4. Radionuclide therapy revisited.
Hoefnagel CA
Eur J Nucl Med; 1991; 18(6):408-31. PubMed ID: 1879447
[TBL] [Abstract][Full Text] [Related]
5. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
DeNardo GL; Siantar CL; DeNardo SJ
Cancer Biother Radiopharm; 2002 Feb; 17(1):107-18. PubMed ID: 11915167
[TBL] [Abstract][Full Text] [Related]
6. Relevance of radiobiological concepts in radionuclide therapy of cancer.
Kumar C; Shetake N; Desai S; Kumar A; Samuel G; Pandey BN
Int J Radiat Biol; 2016; 92(4):173-86. PubMed ID: 26917443
[TBL] [Abstract][Full Text] [Related]
7. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.
Prior JO; Gillessen S; Wirth M; Dale W; Aapro M; Oyen WJG
Eur J Cancer; 2017 May; 77():127-139. PubMed ID: 28391026
[TBL] [Abstract][Full Text] [Related]
8. Preclinical animal research on therapy dosimetry with dual isotopes.
Konijnenberg MW; de Jong M
Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S19-27. PubMed ID: 21484379
[TBL] [Abstract][Full Text] [Related]
9. Radiation protection in therapy with radiopharmaceuticals.
Hosono M
Int J Radiat Biol; 2019 Oct; 95(10):1427-1430. PubMed ID: 30265162
[No Abstract] [Full Text] [Related]
10. Radionuclide therapy.
Chatal JF; Hoefnagel CA
Lancet; 1999 Sep; 354(9182):931-5. PubMed ID: 10489968
[TBL] [Abstract][Full Text] [Related]
11. Patient dosimetry in radionuclide therapy: the whys and the wherefores.
Thierens HM; Monsieurs MA; Bacher K
Nucl Med Commun; 2005 Jul; 26(7):593-9. PubMed ID: 15942479
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response.
Meredith R
Cancer Biother Radiopharm; 2002 Feb; 17(1):83-99. PubMed ID: 11915176
[TBL] [Abstract][Full Text] [Related]
13. Introduction to kidney dose-response for radionuclide therapy.
Sgouros G
Cancer Biother Radiopharm; 2004 Jun; 19(3):357-8. PubMed ID: 15285882
[No Abstract] [Full Text] [Related]
14. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.
Lawhn-Heath C; Hope TA; Martinez J; Fung EK; Shin J; Seo Y; Flavell RR
Lancet Oncol; 2022 Feb; 23(2):e75-e87. PubMed ID: 35114134
[TBL] [Abstract][Full Text] [Related]
15. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
16. The radiation biology of radioimmunotherapy.
Dixon KL
Nucl Med Commun; 2003 Sep; 24(9):951-7. PubMed ID: 12960593
[TBL] [Abstract][Full Text] [Related]
17. Targeted radionuclide therapy--an overview.
Dash A; Knapp FF; Pillai MR
Curr Radiopharm; 2013 Sep; 6(3):152-80. PubMed ID: 24059327
[TBL] [Abstract][Full Text] [Related]
18. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
19. Leveraging the power of non-radium radionuclide treatments in bone metastases.
Thapa P; Basu S
Q J Nucl Med Mol Imaging; 2019 Jun; 63(2):159-169. PubMed ID: 31271269
[TBL] [Abstract][Full Text] [Related]
20. Renal dosimetry in peptide radionuclide receptor therapy.
Siegel JA; Stabin MG; Sharkey RM
Cancer Biother Radiopharm; 2010 Oct; 25(5):581-8. PubMed ID: 20849308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
